Celularity Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Celularity Inc. (CELU) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$5.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-05-08.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2025-05-08
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-12-31 was -$3.00K.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-09-30 was -$2.00K.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-06-30 was $0.00.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$5.00K, a 103.42% decline from fiscal 2023.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $146.00K, a 1522.22% increase from fiscal 2022.
- Celularity Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $9.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$5.00K derived: sum of 2 quarters · filed 2025-05-08 | -$5.00K derived: sum of 3 quarters · filed 2025-05-08 | -$5.00K 10-K · filed 2025-05-08 |
| 2024-09-30 | -$2.00K 10-Q · filed 2024-12-06 | -$2.00K derived: sum of 2 quarters · filed 2024-12-06 | -$2.00K 10-Q · filed 2024-12-06 | -$2.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | -$2.40M derived: sum of 3 quarters · filed 2025-05-08 | -$2.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-10-16 | -$2.40M derived: sum of 2 quarters · filed 2025-05-08 | -$2.40M derived: sum of 3 quarters · filed 2025-05-08 | -$2.66M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | -$2.40M derived: sum of 2 quarters · filed 2025-05-08 | -$2.66M derived: sum of 3 quarters · filed 2025-05-08 | $146.00K 10-K · filed 2025-05-08 |
| 2023-09-30 | $0.00 10-Q · filed 2024-12-06 | -$269.00K derived: sum of 2 quarters · filed 2024-12-06 | $2.54M 10-Q · filed 2024-12-06 | $2.16M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | -$269.00K 10-Q · filed 2024-11-07 | $2.39M 10-Q · filed 2024-11-07 | $2.16M derived: sum of 3 quarters · filed 2024-11-07 | $2.40M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $2.66M 10-Q · filed 2024-10-16 | $2.43M derived: sum of 2 quarters · filed 2024-10-16 | $2.67M derived: sum of 3 quarters · filed 2024-10-16 | $2.67M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $9.00K derived: sum of 2 quarters · filed 2024-07-30 | $9.00K derived: sum of 3 quarters · filed 2024-07-30 | $9.00K 10-K · filed 2024-07-30 |
| 2022-09-30 | $236.00K 10-Q · filed 2024-01-03 | $236.00K derived: sum of 2 quarters · filed 2024-01-03 | $236.00K 10-Q · filed 2024-01-03 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |